{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:40:49Z","timestamp":1793018449957,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031715","name":"Ocular Therapeutix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031715","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajo.2024.11.021","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:28:08Z","timestamp":1733315288000},"page":"268-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1\/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results"],"prefix":"10.1016","volume":"271","author":[{"given":"Paul","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-2897","authenticated-orcid":false,"given":"David","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-9030","authenticated-orcid":false,"given":"Andreas","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0328-7927","authenticated-orcid":false,"given":"Robert","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-6599","authenticated-orcid":false,"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-495X","authenticated-orcid":false,"given":"Antonio","family":"Yaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ah","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Curtiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-7519","authenticated-orcid":false,"given":"Nadia K.","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2024.11.021_bib0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2024.11.021_bib0002","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1167\/iovs.06-0971","article-title":"Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations","volume":"48","author":"Sandberg","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9549","key":"10.1016\/j.ajo.2024.11.021_bib0003","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.ajo.2024.11.021_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40123-022-00602-y","article-title":"X-linked retinitis pigmentosa gene therapy: preclinical aspects","volume":"12","author":"Mansouri","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.11.021_bib0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/hmg\/ddp469","article-title":"Human retinopathy-associated ciliary protein retinitis pigmentosa GTPase regulator mediates cilia-dependent vertebrate development","volume":"19","author":"Ghosh","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0006","year":"2021"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0007","series-title":"Phase 3 Randomized, Controlled Study of AAV5-RPGR For the Treatment of X-Linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene","year":"2023"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0008","series-title":"A Dose Escalation (Phase 1), and Dose Expansion (Phase 2\/3) Clinical Trial of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)","year":"2023"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0009","series-title":"An Open-Label, Single-Center, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-Associated X-Linked Retinitis Pigmentosa","year":"2023"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0010","series-title":"Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR For the Treatment of Japanese X-Linked Retinitis Pigmentosa Associated With Pathogenic Variants in Retinitis Pigmentosa GTPase Regulator (RPGR)","year":"2024"},{"key":"10.1016\/j.ajo.2024.11.021_sbref0011","series-title":"An Open-Label, Phase 1\/2 Trial of Gene Therapy 4D-125 in Males With X-Linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene","year":"2023"},{"key":"10.1016\/j.ajo.2024.11.021_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"10.1016\/j.ajo.2024.11.021_bib0013","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.oret.2022.06.013","article-title":"Intravitreal delivery of rAAV2tYF-CB-hRS1 vector for gene augmentation therapy in patients with X-linked retinoschisis: 1-year clinical results","volume":"6","author":"Pennesi","year":"2022","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2024.11.021_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100050","article-title":"An optimized treatment protocol for subretinal injections limits intravitreal vector distribution","volume":"1","author":"Reichel","year":"2021","journal-title":"Ophthalmol Sci"},{"issue":"14","key":"10.1016\/j.ajo.2024.11.021_bib0015","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1093\/hmg\/ddv134","article-title":"A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration","volume":"24","author":"Wu","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.ajo.2024.11.021_bib0016","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1089\/hum.2018.244","article-title":"Development of a molecularly stable gene therapy vector for the treatment of RPGR-associated X-linked retinitis pigmentosa","volume":"30","author":"Giacalone","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.11.021_bib0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14712598.2020.1680635","article-title":"RPGR gene therapy presents challenges in cloning the coding sequence","volume":"20","author":"Camara","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2024.11.021_bib0018","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1242\/bio.016816","article-title":"The carboxyl terminal mutational hotspot of the ciliary disease protein RPGRORF15 (retinitis pigmentosa GTPase regulator) is glutamylated in vivo","volume":"5","author":"Rao","year":"2016","journal-title":"Biol Open"},{"issue":"21","key":"10.1016\/j.ajo.2024.11.021_bib0019","doi-asserted-by":"crossref","first-page":"E2925","DOI":"10.1073\/pnas.1523201113","article-title":"Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations","volume":"113","author":"Sun","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.ajo.2024.11.021_bib0020","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/v11121138","article-title":"Chimeric capsid proteins impact transduction efficiency of haploid adeno-associated virus vectors","volume":"11","author":"Chai","year":"2019","journal-title":"Viruses"},{"issue":"R1","key":"10.1016\/j.ajo.2024.11.021_bib0021","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1093\/hmg\/ddx163","article-title":"Photoreceptor outer segment as a sink for membrane proteins: hypothesis and implications in retinal ciliopathies","volume":"26","author":"Seo","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.ajo.2024.11.021_bib0022","first-page":"369","article-title":"X-linked retinitis pigmentosa. Profile of clinical findings","volume":"106","author":"Fishman","year":"1988","journal-title":"Arch Ophthalmol Chic Ill 1960."},{"issue":"7","key":"10.1016\/j.ajo.2024.11.021_bib0023","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1073\/pnas.97.7.3649","article-title":"A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3)","volume":"97","author":"Hong","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.ajo.2024.11.021_bib0024","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/hmg\/11.9.993","article-title":"Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration","volume":"11","author":"Zhang","year":"2002","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.ajo.2024.11.021_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal Injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ajo.2024.11.021_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.846782","article-title":"Subretinal therapy: technological solutions to surgical and immunological challenges","volume":"9","author":"Ladha","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.ajo.2024.11.021_bib0027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse Retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ajo.2024.11.021_bib0028","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","article-title":"Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations","volume":"141","author":"von Krusenstiern","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2024.11.021_bib0029","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1167\/iovs.11-7895","article-title":"Glaucoma research community and FDA look to the future, II: NEI\/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function","volume":"52","author":"Weinreb","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2024.11.021_bib0030","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/OPX.0b013e31825da18c","article-title":"Comparison between MP-1 and Humphrey visual field defects in glaucoma and retinitis pigmentosa","volume":"89","author":"Acton","year":"2012","journal-title":"Optom Vis Sci Off Publ Am Acad Optom"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942400552X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942400552X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:04:48Z","timestamp":1764839088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942400552X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S000293942400552X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.11.021","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1\/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}